GET DAILY SIGNALSActinium Pharmaceuticals (ATNM): Insights into Its Targeted Radiotherapy Pipeline
Key Takeaways
- ATNM is the ticker for Actinium Pharmaceuticals, Inc., a clinical-stage biotechnology company developing targeted radiotherapies for cancer.
- The company's core technology platform is Antibody Radiation Conjugates (ARCs), which combine cancer-targeting antibodies with radioactive isotopes to deliver radiation directly to tumor cells.
- Its lead programs include ATNM-400, Actimab-A, Iomab-B, and Iomab-ACT, targeting solid tumors and blood cancers such as acute myeloid leukemia (AML).
- As a clinical-stage company, Actinium has not yet received regulatory approval for any product and generates no commercial revenue, funding itself primarily through equity sales and partnerships.
- Actinium has a research collaboration with the National Cancer Institute (NCI) and a licensing agreement with Immedica for the commercialization of Iomab-B in Europe, the Middle East, and North Africa.
Introduction
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies intended to improve outcomes for cancer patients who have failed existing treatments. The company's approach combines the precision of antibodies with the cell-killing power of radiation, an emerging field known as radiopharmaceuticals. Investors follow ATNM primarily because of its differentiated pipeline of Antibody Radiation Conjugates (ARCs) and its positioning within the rapidly growing targeted radiotherapy market.
Company Overview and Business Model
Actinium Pharmaceuticals was incorporated in Delaware in 2013 and is headquartered at 100 Park Avenue in New York City. The company traces its focus on radiotherapies back to its founding, which sources cite around 2000, and it operates as a single-segment biotechnology business devoted to research and clinical development.
The company's business model is centered on discovering and developing novel radiopharmaceutical product candidates, then advancing them through clinical trials with the goal of securing regulatory approval or licensing partnerships. Like most clinical-stage biotechs, Actinium does not yet sell any products. Its financial profile reflects this stage of development: the company reported no product revenue and a net loss of approximately $33.9 million for 2025, with operations funded largely through equity offerings, grants, and licensing agreements.
Core Technology and Pipeline
Actinium's platform is built around Antibody Radiation Conjugates, which link a targeting antibody to a radioactive isotope such as Actinium-225 (Ac-225) or Iodine-131 (I-131). The antibody seeks out specific proteins on cancer cells, allowing the attached radiation to kill tumors while limiting damage to healthy tissue. The company's lead programs include:
- ATNM-400 – a first-in-class Ac-225 radioconjugate targeting a novel, non-PSMA antigen with preclinical activity across solid tumors including metastatic prostate cancer, non-small cell lung cancer, and breast cancer.
- Actimab-A – a CD33-targeted Ac-225 therapy being developed for AML and myelodysplastic syndrome (MDS), as well as a mechanism to enhance checkpoint inhibitor efficacy in solid tumors.
- Iomab-B – a CD45-targeted I-131 conditioning agent for bone marrow transplant in patients with relapsed or refractory AML.
- Iomab-ACT – a conditioning platform designed to improve access to cell and gene therapies such as CAR-T.
Partnerships and Competitive Positioning
Actinium holds a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to develop Actimab-A in AML and other myeloid malignancies. In 2022, the company licensed exclusive rights to commercialize Iomab-B in the EUMENA region (Europe, Middle East, and North Africa) to Immedica. The company also maintains a substantial intellectual property portfolio, citing roughly 250 patents and patent applications, including technology for cyclotron-based production of Ac-225.
Within the radiopharmaceutical field, Actinium competes against large pharmaceutical companies and smaller clinical-stage developers. Its market position is differentiated by a focus on novel, non-PSMA and non-SSTR targets, in contrast to many competitors concentrated on validated targets such as PSMA in prostate cancer.
Why Investors Follow ATNM
Actinium attracts attention because targeted radiotherapy is an area of growing clinical and commercial validation. The company's biology-driven approach seeks first-in-class targets with "pan-tumor" potential, which could address large patient populations across multiple cancer types. Its late-stage hematology programs, supported by clinical data across hundreds of patients, offer potential partnership and value-creation opportunities. The company's efforts to build an integrated supply chain, including internal manufacturing capabilities and proprietary isotope-production technology, are also viewed as strategic differentiators in a field where isotope supply has historically been a bottleneck. In my analysis, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Risks and Important Considerations
Investing in Actinium carries substantial risk typical of clinical-stage biotechnology. The company has no approved products, no commercial revenue, and has incurred losses every year since inception. Its future depends heavily on the success of clinical trials, which may fail or face regulatory setbacks. The company also requires additional financing to continue operations and development. Regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) are uncertain, and the company faces intense competition from better-resourced pharmaceutical firms. Supply of radioactive isotopes, manufacturing scale-up, and reliance on third parties are additional operational risks. Investors should carefully weigh these factors against the company's longer-term potential.
Using Tickeron’s AI Screener in Biotech Research
In my research process, I often turn to Tickeron’s AI Screener to identify and compare opportunities in sectors like biotechnology. The platform helps apply filters based on technical indicators, fundamentals, volatility, trends, and AI-generated signals, making it easier to surface ideas that fit a given strategy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ATNM in upward trend: 10-day moving average moved above 50-day moving average on October 20, 2026
The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +23.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 165 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATNM as a result. In 77 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for ATNM turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.498). P/E Ratio (4.086) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology
Advertisement